Open AccessAntinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial
Author(s) -
Dean Follmann,
Holly Janes,
Olive D. Buhule,
Honghong Zhou,
Bethany Girard,
Kristen Marks,
Karen L. Kotloff,
Michaël Desjardins,
Lawrence Corey,
Kathleen M. Neuzil,
Jacqueline M. Miller,
Hana M. El Sahly,
Lindsey R. Baden
Publication year - 2022
Publication title -
annals of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.839
H-Index - 390
eISSN - 1539-3704
pISSN - 0003-4819
DOI - 10.7326/m22-1300
Subject(s) - medicine , covid-19 , placebo , double blinded , randomized controlled trial , clinical trial , virology , antibody , antibody response , immunology , pathology , outbreak , infectious disease (medical specialty) , alternative medicine , disease
Immunoassays for determining past SARS-CoV-2 infection have not been systematically evaluated in vaccinated persons in comparison with unvaccinated persons.